Faculty
Oncology Division
James J. Hsieh, MD, PhD
Professor
Department of Medicine
Oncology Division
Molecular Oncology
Medical Oncology
Clinical Interests
- Kidney cancer
Research Interests
- Kidney cancer metabolomics
- Genomics, Epigenetics
- Therapeutics, Precision Medicine
- Translational kidney cancer research
- Mouse tumor models, Mouse development
- Drug development
- Taspase1, Notch, MLL, Stem cells
Contact
- 314-454-8681 (office)
- 314-273-1688 (lab)
- 314-362-7086 (fax)
- jhsieh@wustl.edu
- Division of Oncology
Campus Box 8069
Washington University
660 South Euclid Avenue
St. Louis, MO 63110 - 554 McDonnell Medical Sciences Building (office)
Biosketch
| Education | |
|---|---|
| 1983-1990 | MD, Taipei Medical University, Taipei, Taiwan |
| 1992-1996 | PhD, Johns Hopkins University School of Medicine, Baltimore, MD |
| Post-doctoral Training | |
| 1996-1997 | Postdoctoral Fellow, Johns Hopkins University School of Medicine, Baltimore, MD |
| 1997-1999 | Medicine Intern/Resident, Barnes Jewish Hospital, St. Louis, MO |
| 1999-2000 | Oncology Fellow, Barnes Jewish Hospital, St. Louis, MO |
| 2000-2003 | Oncology Fellow, Dana Farber Cancer Institute, Boston, MA |
| Academic Positions | |
| 2003-2004 | Instructor, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA |
| 2004-2010 | Assistant Professor, Washington University School of Medicine, St. Louis, MO |
| 2010 | Associate Professor, Washington University School of Medicine, St. Louis, MO |
| 2010-2016 | Associate Member, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 2011-2016 | Associate Professor, Weill Medical College, Cornell University, New York, NY |
| 2017-present | Professor, Washington University School of Medicine, St. Louis, MO |
| Board Certification | |
| 2000-2010 | American Board of Internal Medicine |
| 2002-2022 | American Board of Internal Medicine, Medical Oncology |
| Professional Memberships | |
| 1996-present | Phi Beta Kappa |
| 2000-present | American Society of Clinical Oncology |
| 2004-2013 | American Society of Hematology |
| 2009-present | Society of Chinese Bioscientists in America |
| 2009-present | American Association for Cancer Research |
| 2010-present | American Society for Clinical Investigation |
| Honors & Awards | |
| 1990 | Graduate summa cum laude (3/158), Taipei Medical University |
| 1996 | Nineteenth Annual Young Investigators' Award, The Johns Hopkins University School of Medicine |
| 1996 | Phi Beta Kappa |
| 2000 | Physician-Scientist Fellowship Award, HHMI |
| 2003 | Howard Temin Award, K01, NCI |
| 2005 | Edward Mallinckrodt Jr. Foundation Award |
| 2006 | Basic Research Scholar, American Society of Hematology |
| 2009 | Basic Research Scholar, American Cancer Society |
| 2010 | American Society for Clinical Investigation |
| 2015 | Member, Medical and Scientific Steering Committee, Kidney Cancer Association (KCA) |
| Committees | |
| 2008-2010 | ACS IRG Review Committee, Washington University, St. Louis, MO |
| 2011-2016 | MSK Translational Kidney Cancer Research Program, Founder/Director |
| 2011-present | TCGA Kidney Cancer Genomics Working Group |
| 2012-2013 | MSK Cycle for Survival Review Committee |
| 2012-2014 | AACR Kure It Kidney Cancer Review Committee |
| 2012 | Clinical TCGA, Kidney Cancer, Founder |
| 2012 | Rare Kidney Cancer Association, Founder |
| 2013-2015 | AACR Clinical and Translational Research Grants Review Committee |
| 2014-2015 | DOD CDMRP, Kidney Cancer Review Committee Chair |
| 2015 | AUA Review Committee |
| 2015-present | KCA Steering Committee |
| 2017-present | ASCI Young Investigator Review Committee |
| 2017-present | NCI Clinical Proteome Tumor Analysis Consortium RCC |
| 2017-present | Renal Cancer Clinical Trial Consortium (RCCTC) Founder |
| 2018 | NCI P01 Review Committee |
| Editorial Boards | |
| Journal of Kidney Cancer and VHL | |
| Kidney Cancer | |
| Cell Stress | |
| Translational Cancer Research | |
| 2020-present | Editor-in-Chief, Clinical Genitourinary Cancer, Elsevier |
